НEMODIALIASIS AND COVID-19 (ANALYSIS OF THE FIRST YEAR OF THE PANDEMIC IN MAKHACHKALA)
https://doi.org/10.36485/1561-6274-2022-26-2-85-92
Abstract
BACKGROUND. Patients receiving treatment with programmed hemodialysis are at high risk for the incidence of COVID-19. THE AIM: to analyze the clinical picture, features of the course, risk factors and treatment options in COVID-19 patients treated with programmed hemodialysis in Makhachkala. PATIENTS AND METHODS. 162 patients (87 men and 75 women) were treated with HD for terminal renal failure were under observation in the GBU RD "RKB" of Makhachkala, repurposed to provide medical care to patients infected with SARS-CoV-2 from April 2019 to April 2020. The study was single-center, retrospective and uncontrolled. The end point of observation was considered to be the patient's discharge from the hospital or death. Patients who continued treatment at the end of the study were excluded from it. RESULTS. Infection with SARS-CoV-2 in 101 (62.3%) patients was confirmed by PCR results, and in the rest – by a characteristic pattern determined by CT of the chest organs. The fatal outcome of COVID-19 in patients with HD was associated with a more severe and widespread lung lesion (CT-3 and CT-4), which was diagnosed significantly more often compared to the surviving patients. In a significant number of patients with endstage CKD treated with HD, it is characterized by a severe course and an unfavorable prognosis. In this regard, there is a need to search for effective and safe methods of prevention and treatment in groups at increased risk of infection and severe COVID-19. CONCLUSION. Patients with CKD have an increased risk of developing severe COVID-19. Concomitant cardiovascular diseases and diabetes mellitus may predispose to this. Given the availability of a vaccine or approved therapy, nephrologists should advise patients with CKD to follow the recommendations of social isolation.
About the Authors
P. G. Gadzhieva
A.V. Vishnevsky Republican Clinical Hospital
Russian Federation
Russian Federation
Gadzhieva Patimatzagra Gadzhievna, hemodialysis department, head of the department
367000, Republic of Dagestan, Makhachkala, Korkmaova str., 9, sq. 9
Tel.: 8-989-678-75-75
Z. A. Agalavova
A.V. Vishnevsky Republican Clinical Hospital
Russian Federation
Russian Federation
Agalavova Zarema Alimurzaevna, hemodialysis department, nephrologist
367000, Republic of Dagestan, Makhachkala, Gusaeva str., house 4, sq.3
tel.: 8-989-876-81-33
M. J. Gadzhiyavdibirova
A.V. Vishnevsky Republican Clinical Hospital
Russian Federation
Russian Federation
Gadzhiyavdibirova Madina Jamalkhanovna, hemodialysis department, nephrologist
367026, Republic of Dagestan, Makhachkala, Shamil ave., 42, sq. 50
Tel.: 8-988-442-46-71
L. B. Gasanova
A.V. Vishnevsky Republican Clinical Hospital
Russian Federation
Russian Federation
Hasanova Leila Bilalovna, hemodialysis department, nephrologist
367027, Republic of Dagestan, Makhachkala, Magomedtagirova str., 180 "A", sq. 95
tel.: 8-988-467-94-11
References
1. Bai Y, Yao L, Wei T et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA 2020 Apr 14;323(14):1406–1407. doi:10.1001/jama.2020.2565
2. Li R, Pei S, Chen B et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARSCoV-2). Science 2020 May 1;368(6490):489–493. doi:10.1126/science.abb3221
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18): 1708–1720. doi:10.1056/NEJMoa2002032
4. Kwenandar F, Japar KV, Damay V, Hariyanto TI, Tanaka M, Lugito NPH, Kurniawan A. Coronavirus disease 2019 and cardiovascular system: A narrative review. Int J Cardiol Heart Vasc 2020 Jun 3;29:100557. doi:10.1016/j.ijcha.2020.100557
5. Rubens JH, Karakousis PC, Jain SK. Stability and Viability of SARS-CoV-2. N Engl J Med 2020 May 14;382(20):1962–1963. doi:10.1056/NEJMc2007942
6. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020 Apr 3;69(13):382–386. doi:10.15585/mmwr.mm6913e2
7. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020 May;97(5):829–838. doi:10.1016/j.kint.2020.03.005
8. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int 2020 May;97(5):824–828. doi:10.1016/j.kint.2020.03.001
9. Mancia G, Rea F, Ludergnani M et al. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020. http://www.nejm.org/doi/10.1056/NEJMoa2006923
10. Martin-Sanchez D, Fontecha-Barriuso M, Carrasco S et al. TWEAK and RIPK1 mediate a second wave of cell death during AKI. Proc Natl Acad Sci USA 2018;115:4182–4187. http://doi.org/10.1073/pnas.1716578115
11. Su H, Yang M, Wan C et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020. https://linkinghub.elsevier.com/retrieve/pii/S0085253820303690
12. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020 Apr;20(4):411–412. doi:10.1016/S1473-3099(20)30113-4
13. Peleg Y, Kudose S, D’Agati V et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int Rep 2020. https://linkinghub.elsevier.com/retrieve/
14. Ronco C, Reis T, De Rosa S. Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum. Blood Purif 2020;49(3):255–258. doi:10.1159/000507039
15. Ma Y, Diao B, Lv X, Zhu J, Liang W, Liu L et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan China. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.24.20027201
16. Li C, Yonglong M, Can T, Dongdong M, Sheng W, Haifeng L et al. An Analysis on the clinical features of MHD patients with coronavirus disease 2019: a single center study. 2020. doi: https://doi.org/10.21203/rs.3.rs-18043/v1
17. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, Maffei C, Possenti S, Piva S, Latronico N, Focà E, Castelli F, Gaggia P, Movilli E, Bove S, Malberti F, Farina M, Bracchi M, Costantino EM, Bossini N, Gaggiotti M, Scolari F; Brescia Renal COVID Task Force. Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney Int Rep 2020 Apr 4;5(5):580–585. doi:10.1016/j.ekir.2020.04.001
18. Bonny V, Maillard A, Mousseaux C, Plaçais L, Richier Q. COVID-19: physiopathologie d’une maladie à plusieurs visages [COVID-19: Pathogenesis of a multi-faceted disease]. Rev Med Interne 2020 Jun;41(6):375–389. French. doi:10.1016/j.revmed.2020.05.003
19. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020[J]. China CDC Weekly, 2020, 2(8): 113–122. doi:10.46234/ccdcw2020.032
20. Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the Kidney: From Epidemiology to Clinical Practice. J Clin Med 2020 Aug 4;9(8):2506. doi:10.3390/jcm9082506
21. Cheng Y, Luo R, Wang K et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020 May;97(5):829–838. doi:10.1016/j.kint.2020.03.005
22. Wang L, Li X, Chen H et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am J Nephrol 2020;51(5):343–348. doi:10.1159/000507471
23. Zhang J, Litvinova M, Wang W et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis 2020 Jul;20(7):793–802. doi:10.1016/S1473-3099(20)30230-9
24. Wang R, Liao C, He H et al. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. Am J Kidney Dis 2020 Jul;76(1):141–143. doi:10.1053/j.ajkd.2020.03.009
25. Arslan H, Musabak U, Ayvazoglu Soy EH et al. Incidence and Immunologic Analysis of Coronavirus Disease (COVID-19) in Hemodialysis Patients:A Single-Center Experience. Exp Clin Transplant 2020 Jun;18(3):275–283. doi:10.6002/ect.2020.0194
26. Boraschi P. COVID-19 Pulmonary Involvement: Is Really an Interstitial Pneumonia? Acad Radiol 2020 Jun;27(6):900. doi:10.1016/j.acra.2020.04.010
27. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020 Jun;52(6):1193–1194. doi:10.1007/s11255-020-02451-9
28. Xiong F, Tang H, Liu L et al. Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China. J Am Soc Nephrol 2020 Jul;31(7):1387–1397. doi:10.1681/ASN.2020030354
29. Rombolà G, Brunini F. COVID-19 and dialysis: why we should be worried. J Nephrol 2020 Jun;33(3):401–403. doi:10.1007/s40620-020-00737-w
Review
For citations:
Gadzhieva P.G., Agalavova Z.A., Gadzhiyavdibirova M.J., Gasanova L.B. НEMODIALIASIS AND COVID-19 (ANALYSIS OF THE FIRST YEAR OF THE PANDEMIC IN MAKHACHKALA). Nephrology (Saint-Petersburg). 2022;26(2):85=92. (In Russ.) https://doi.org/10.36485/1561-6274-2022-26-2-85-92
Views:
311
Email this article 